Physician profile
Miles Murphy
NPI 1699701623
$53,801.98
in general payments reported to CMS, 2019-2025
31 companies · $3,371 in 2025
The $3,371 reported for 2025 was more than what 88% of Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) providers received nationally (typical 2025 total: $413).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $4,083 · 2021: $2,265 · 2022: $2,691 · 2023: $1,737 · 2024: $2,271 · 2025: $3,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,344 · Consulting Fee: $1,150 · Travel and Lodging: $865 · Honoraria: $700 · Education: $299 · Entertainment: $21.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,343.64 |
| Consulting Fee | $1,150.00 |
| Travel and Lodging | $864.78 |
| Honoraria | $700.00 |
| Education | $298.98 |
| Entertainment | $21.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $42,651.68 | 2019-2025 | Solyx Sis System, Axonics, Polyform |
| Coloplast Corp | $2,291.14 | 2019-2025 | |
| Astellas Pharma US INC | $1,624.63 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $1,198.09 | 2021-2025 | |
| Medtronic, INC. | $1,036.77 | 2022-2025 | Altaviva, Interstim |
| Axonics, INC. | $960.98 | 2020-2024 | Axonics, Bulkamid |
| Teleflex LLC | $730.00 | 2024-2025 | Barrigel, Solesta |
| Caldera Medical, INC | $695.52 | 2020-2025 | Desara |
| Zoll Medical Corporation | $491.67 | 2021 | |
| Pfizer INC. | $398.11 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $349.43 | 2023-2025 | Gemtesa |
| Escala Medical INC. | $209.56 | 2024-2025 | |
| Femselect INC. | $208.83 | 2022-2025 | Enplace |
| Urovant Sciences INC | $206.99 | 2021-2022 | |
| Allergan, INC. | $189.11 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $115.92 | 2022 | |
| Therapeuticsmd, INC. | $69.41 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $66.42 | 2019-2020 | |
| Renovia INC | $45.59 | 2021 | |
| Valencia Technologies Corporation | $39.98 | 2023 | Ecoin Device Kit |
| Hologic Sales and Service, LLC | $35.83 | 2019 | |
| Bluewind Medical | $25.98 | 2024 | Revi |
| Avadel Specialty Pharmaceuticals, LLC | $24.95 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $23.32 | 2023 | Seglentis |
| Avation Medical, INC. | $21.67 | 2025 | Vivally System |
| Provepharm INC. | $21.15 | 2024 | Bludigo |
| Millicent US INC | $19.95 | 2025 | Femring, Intrarosa |
| 180 Medical, INC. | $19.50 | 2021 | |
| Coopersurgical, INC. | $16.54 | 2021 | |
| Ferring Pharmaceuticals INC. | $13.26 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$748.70 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miles Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.